Balchem reported results for the quarter ended September 30, 2026, with net sales of $290.7 million, up 8.6% from the prior year quarter, and GAAP net earnings of $46.7 million, up 16.0%. Diluted GAAP earnings per share were $1.46 versus $1.24, and all three reporting segments grew sales and earnings from operations, which points to improving results for shareholders.
Net sales were $290.7 million, up 8.6%; GAAP net earnings were $46.7 million, up 16.0%.
GAAP diluted EPS was $1.46 versus $1.24; adjusted EPS was $1.57 versus $1.35.
Free cash flow was $57.9 million; the company repurchased about $28 million of common stock in the quarter.
Net debt was $57.7 million with a leverage ratio of 0.2 times on a net debt basis.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Balchem Corporation's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$1.04B
+8.8%
$4.75
+20.9%
14.9%
FY2024
$953.68M
+3.4%
$3.93
+17.3%
13.5%
FY2023
$922.44M
-2.1%
$3.35
+3.1%
11.8%
FY2022
$942.36M
+17.9%
$3.25
+10.5%
11.2%
FY2021
$799.02M
+13.6%
$2.94
+13.1%
12.0%
Frequently asked questions
When is Balchem's next earnings date?
Balchem has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Balchem earn last quarter?
For the quarter ended Sep 2026, Balchem reported diluted EPS of $1.46 (+17.7% year over year) on revenue of $290.66M (+8.6%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.